Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06058949 · ClinicalTrials.gov registry record · NA

Health Protection and Promotion of Sign Language Interpreters Through Implementation of Total Worker Health®

A NA study of Well-Being, Psychological, sponsored by University of Rochester.

Active
Registry status
NA
Development phase
133
Enrollment target
1
Study location

NCT06058949: Active NA study of Well-Being, Psychological, sponsored by University of Rochester.

NCT06058949 is a NA study of Well-Being, Psychological that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 133 participants, below the 391-participant average among 19 other Well-Being, Psychological trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06058949, a NA study of Well-Being, Psychological, is active but no longer recruiting, sponsored by University of Rochester.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
133 participants
Enrollment target
1
Study location

Study Summary

Using mixed-methods and a clinical efficacy trial design, the overall objective of this study will employ implementation strategies to adapt and evaluate a previous integrated Total Worker Health® (TWH®) program and pilot test its efficacy on sign language interpreter well-being. The central hypothesis is that interpreters in the health protection and promotion program (intervention) will demonstrate significantly improved well-being compared to those in a general health program (control).

Primary Outcome

TARS-1 measures acceptability using six items (1=strongly disagree; 6=strongly agree) and demonstrates good test-retest reliability, internal consistency, and construct and concurrent validity. The scale ranges from 6 to 36 with higher scores indicating better acceptability.

Conditions Studied

Interventions

  • BEHAVIORAL Health Protection and Promotion
  • BEHAVIORAL General Health Program

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2024-05-01
Est. Completion 2026-08-31
Phase NA
University of Rochester

636 total trials

What the registry record for NCT06058949 still lists

NCT06058949 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 391-participant average among 19 other Well-Being, Psychological trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Well-Being, Psychological appearing as the primary indexed condition, and to 2 interventions - of which Health Protection and Promotion is the first listed.

NCT06058949 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06058949 about?

NCT06058949 is a clinical study titled "Health Protection and Promotion of Sign Language Interpreters Through Implementation of Total Worker Health®". Using mixed-methods and a clinical efficacy trial design, the overall objective of this study will employ implementation strategies to adapt and evaluate a previous integrated Total Worker Health® (TWH®) program and pilot test its efficacy on sign language interpreter well-being. The central hypothe...

What is the current status of trial NCT06058949?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 133 participants. The study started on 2024-05-01. Estimated completion is 2026-08-31.

What conditions does trial NCT06058949 study?

This clinical trial studies the following conditions: Well-Being, Psychological.

What interventions are being tested in trial NCT06058949?

The interventions under investigation include: Health Protection and Promotion (BEHAVIORAL), General Health Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06058949?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06058949 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Well-Being, Psychological

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06058949's enrollment target sits among peer trials

133 11th of 19 higher than 9 of 19 other Well-Being, Psychological trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Well-Being, Psychological trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04276870 · 133 participants · Phase 2

    Orphan Indications for CD19 Redirected Autologous T Cells

  • NCT04671771 · 133 participants · NA

    A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

  • NCT05610085 · 133 participants · Phase 2

    A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

  • NCT06206486 · 133 participants

    The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06058949, the US trial registry maintained by the National Library of Medicine. NCT06058949 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.